UNSPSC 51333406: Lorpiprazole

This classification denotes an antipsychotic agent with the molecular formula C21H26F3N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M14O7T47Q, chemically known as (- )-cis-5,5a,6,7,8,8a-hexahydro-3-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)cyclopenta(3,4)pyrrolo(2,1-c)-s-triazole but generally known as lorpiprazole, which bears US NIH Compound Identifier 3045380. European Medicines Agency schedules Lorpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08590MIG.

UNSPSC 51333406 Lorpiprazole is a Commodity code covering pharmaceutical products, though recent state and local solicitations tagged under this code show procurement activity focused on naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and OTC products rather than lorpiprazole specifically. State and local governments purchasing under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves procurement of finished pharmaceutical products for public health initiatives, community health programs, and state employee health plans, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and specific insurance and employment verification requirements. Contracts typically run two to three years with optional renewals, include quarterly or ongoing delivery schedules, and are awarded on fixed-fee or competitive pricing bases.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors required to work through three authorized wholesalers and subject to a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation.